List of Excipients in Branded Drug DEXMETHYLPHENIDATE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	0781-2682	AMMONIO METHACRYLATE COPOLYMER TYPE A
Sandoz Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	0781-2682	DEXTROSE
Sandoz Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	0781-2682	FD&C BLUE NO. 2

Generic Drugs Containing DEXMETHYLPHENIDATE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	dexmethylphenidate hydrochloride	0093-5550	AMMONIO METHACRYLATE COPOLYMER TYPE B
Teva Pharmaceuticals USA Inc	dexmethylphenidate hydrochloride	0093-5550	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	dexmethylphenidate hydrochloride	0093-5550	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in DEXMETHYLPHENIDATE HYDROCHLORIDE?

# Of NDCs	Excipient
13	1-PROPOXY-2-PROPANOL
2	ACETONE
3	ACETYLTRIBUTYL CITRATE

Dexmethylphenidate Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Dexmethylphenidate hydrochloride is a mature central nervous system stimulant with established immediate-release and extended-release products. The main commercial opportunity is not discovery of a new active ingredient. It is differentiated delivery: controlled release, abuse-deterrent performance, lower excipient burden, improved swallowability, pediatric usability, and reliable generic substitution.

Focalin and Focalin XR are the reference products. Focalin contains dexmethylphenidate hydrochloride in immediate-release tablets. Focalin XR uses a dual-bead extended-release system designed to deliver two dexmethylphenidate doses several hours apart. Generic competition is established, but differentiated formulations can still compete through dosage form, administration flexibility, excipient compatibility, supply reliability, and intellectual property.

What is dexmethylphenidate hydrochloride?

Dexmethylphenidate hydrochloride is the d-enantiomer of methylphenidate hydrochloride. It is a Schedule II controlled substance in the United States and is approved for the treatment of attention-deficit/hyperactivity disorder in patients aged six years and older.[1]

Attribute	Description
Active ingredient	Dexmethylphenidate hydrochloride
Pharmacologic class	CNS stimulant
Reference immediate-release product	Focalin
Reference extended-release product	Focalin XR
U.S. regulatory pathway	NDA products and ANDA generics
Controlled-substance status	Schedule II
Main dosage forms	Immediate-release tablets; extended-release capsules
Primary market	ADHD treatment
Key formulation need	Rapid onset with tolerable duration and predictable exposure

Dexmethylphenidate hydrochloride is water-soluble and sensitive to formulation design because release rate directly affects onset, duration, peak exposure, and adverse-event risk. Excipient selection therefore has a commercial function beyond tablet manufacture.

What excipients are used in dexmethylphenidate hydrochloride products?

The excipients differ materially between immediate-release tablets and extended-release capsules. Product-specific inactive ingredients should be confirmed against the current FDA labeling and DailyMed record because suppliers, colors, and nonfunctional components can change across manufacturers.[1-4]

Immediate-release tablet excipients

Focalin immediate-release tablets use conventional solid-dose excipients, including lactose, pregelatinized starch, microcrystalline cellulose, magnesium stearate, and talc. Tablet colorants vary by strength.[1]

Excipient function	Common material in the reference product	Commercial purpose
Diluent	Lactose	Tablet mass and content uniformity
Binder and disintegrant	Pregelatinized starch	Mechanical strength and breakup
Filler and compression aid	Microcrystalline cellulose	Compactability and robustness
Lubricant	Magnesium stearate	Ejection and manufacturing efficiency
Glidant or processing aid	Talc	Powder flow and anti-sticking
Colorant	Strength-specific colorants	Product identification and differentiation

The main development issues are powder flow, low-dose blend uniformity, tablet hardness, disintegration, and excipient tolerability. Dexmethylphenidate is present at low strengths relative to total tablet mass, so segregation control is important.

Extended-release capsule excipients

Focalin XR uses immediate-release and delayed-release bead populations contained in a capsule. The bead system includes sugar spheres, polymeric coating materials, a binder, talc, and a plasticizer. The exact inactive-ingredient profile is disclosed in the product label.[2]

Functional layer	Typical excipient class	Role
Core	Sugar spheres or multiparticulate starter cores	Provides substrate for drug layering
Drug-layer binder	Povidone or equivalent polymer	Adheres dexmethylphenidate to the core
Release-controlling coat	Ammonio methacrylate copolymer or related polymer	Delays drug release
Processing aid	Talc	Reduces tack and improves coating performance
Plasticizer	Triethyl citrate or equivalent	Improves coating flexibility
Capsule shell	Gelatin or hypromellose	Encloses multiparticulate beads
Opaquifier and colorant	Titanium dioxide and approved colors	Identification and light protection

The release profile is achieved through two bead populations. One population releases dexmethylphenidate promptly. The second has a delayed-release coating. This approach creates a second exposure phase without requiring a midday tablet in the intended dosing regimen.[2]

What excipient strategy is most attractive for dexmethylphenidate?

The strongest strategy depends on the target product.

Strategy 1: Low-cost immediate-release generic

A conventional tablet is the lowest-risk entry path. The formulation can use widely available excipients and standard direct-compression or wet-granulation equipment.

The commercial priorities are:

• Low raw-material cost.
• Robust content uniformity at low drug loading.
• Fast disintegration.
• Low tablet weight.
• Reliable supply of lactose, microcrystalline cellulose, and starch.
• A color system that supports strength differentiation.
• Minimal manufacturing deviations.

A lactose-free version may have limited but identifiable value for patients with lactose intolerance or excipient preferences. A lactose-free formulation using mannitol, microcrystalline cellulose, or selected dibasic calcium phosphate systems could support product differentiation, although the clinical importance of small lactose quantities in tablets is often limited.

Strategy 2: Extended-release multiparticulate product

The extended-release opportunity is more defensible technically. Multiparticulate beads offer control over release through coating weight gain, polymer composition, pore structure, and bead-size distribution.

Key development variables include:

• Drug-layer uniformity.
• Coating thickness and weight gain.
• Polymer permeability.
• Plasticizer concentration.
• Bead size distribution.
• Capsule fill weight.
• Dissolution under pH-shift conditions.
• Food-effect behavior.
• Stability under humidity and temperature stress.
• Dose proportionality across strengths.

A product that can be opened and sprinkled on soft food may have pediatric value, but this claim requires product-specific labeling, stability support, and bioequivalence evidence. The manufacturer cannot assume that sprinkle administration is equivalent to administration of an intact capsule.

Strategy 3: Excipient-reduced or allergen-conscious product

A formulation without lactose, gelatin, selected dyes, or titanium dioxide can address institutional purchasing requirements and patient preferences. The commercial value is strongest when the product also improves administration or supply reliability.

Potential platforms include:

• Hypromellose capsules instead of gelatin.
• Dye-free capsules and tablets.
• Lactose-free tablets.
• Reduced-talc coating systems.
• Plant-derived or synthetic capsule shells.
• Low-nitrite and tightly controlled excipient supply chains.

These changes can create a differentiated product profile, but they do not automatically create strong patent protection. The commercial advantage may depend more on procurement contracts, substitution status, and reliable availability.

What formulation patents protect dexmethylphenidate products?

Formulation patents generally protect the delivery architecture rather than the excipient by itself. Relevant claim types include:

1. Multiparticulate dosage forms containing immediate-release and delayed-release populations.
2. Specific polymer coatings and plasticizer ranges.
3. Dissolution profiles across defined time intervals.
4. Sprinkle administration with food.
5. Capsule systems containing multiple bead populations.
6. Abuse-deterrent matrices or coatings.
7. Stable compositions with defined impurity limits.
8. Manufacturing processes that produce controlled coating thickness.
9. Specific particle-size distributions.
10. Combination products pairing dexmethylphenidate with another active ingredient.

A patent directed only to a known excipient, such as lactose, microcrystalline cellulose, or magnesium stearate, would usually have limited defensibility. Stronger protection comes from a narrow combination of active ingredient, dosage form, release profile, manufacturing parameter, and clinical or pharmacokinetic result.

How strong is the patent estate for Focalin XR?

The original Focalin XR formulation was protected by formulation and delivery patents associated with Novartis and its predecessors. The principal commercial barrier has weakened because generic extended-release dexmethylphenidate products have entered the U.S. market. Current competitive analysis should rely on the FDA Orange Book, ANDA approvals, listed patents, and federal litigation records rather than historical patent claims alone.[5-7]

The remaining opportunity is a follow-on formulation with a materially different release mechanism or administration profile. A new excipient combination must deliver a measurable product advantage, such as:

• Lower peak-related adverse effects.
• Longer coverage without excessive late-day exposure.
• More consistent exposure after food.
• Improved sprinkle performance.
• Lower interpatient variability.
• Reduced capsule swallowing burden.
• Better stability in hot or humid markets.

When does dexmethylphenidate lose exclusivity?

Dexmethylphenidate has already passed the principal U.S. small-molecule exclusivity period for the original products. Focalin and Focalin XR face generic competition, and multiple manufacturers have marketed immediate-release or extended-release products under FDA ANDAs.[5,6]

Exclusivity element	Commercial status
Active ingredient exclusivity	Expired
Original NDA exclusivity	Expired
Generic immediate-release competition	Established
Generic extended-release competition	Established
New formulation exclusivity	Available only for a qualifying new product
Pediatric exclusivity	Historical periods do not block current generic entry
Controlled-substance requirements	Continue despite patent expiry

A new dexmethylphenidate formulation could qualify for three-year new clinical investigation exclusivity under Section 505(b)(2) if approval relies on new clinical investigations essential to approval. Five-year new chemical entity exclusivity is generally unavailable for an enantiomer of a previously approved racemic active ingredient where the relevant statutory criteria are not satisfied.[8]

What is the Orange Book status of dexmethylphenidate products?

The FDA Orange Book identifies approved reference-listed drugs, approved generic equivalents, and listed patent or exclusivity information. Focalin and Focalin XR are the key reference products for dexmethylphenidate hydrochloride in the United States.[5]

Generic applicants may use:

• Paragraph I certifications when no relevant patent is listed.
• Paragraph II certifications when a listed patent has expired.
• Paragraph III certifications when the applicant agrees to wait for patent expiry.
• Paragraph IV certifications when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act. The 30-month stay is not an automatic commercial extension of every patent and depends on the timing and scope of the litigation.[9]

Which companies are challenging dexmethylphenidate exclusivity?

Generic dexmethylphenidate products have been marketed by multiple manufacturers, including large generic companies and specialty pharmaceutical suppliers. The competitive set can change by strength, dosage form, shortage status, and distributor availability.

The relevant competitors include:

• Teva Pharmaceuticals.
• Actavis, now part of Teva or associated corporate successor structures depending on the product record.
• Sandoz.
• Mallinckrodt.
• Hikma.
• Rhodes Pharmaceuticals.
• Other ANDA holders and authorized distributors.

The market should be evaluated at the National Drug Code level. One company may have approval but limited commercial supply, while another may have broad wholesaler distribution. FDA approval alone does not establish meaningful market share.

What generic entry risks exist for dexmethylphenidate?

Generic entry risk is high for conventional immediate-release tablets because the dosage form is simple, the active ingredient is established, and substitution is familiar. Extended-release products present greater technical risk because bioequivalence depends on the full pharmacokinetic profile rather than a single dissolution endpoint.

Product type	Generic entry risk	Main barrier
Immediate-release tablet	High	Low-dose uniformity and manufacturing scale
Extended-release capsule	Moderate to high	Multiparticulate release and PK matching
Sprinkle capsule	Moderate	Administration method and food interaction
Abuse-deterrent product	Moderate	Clinical and in vitro performance evidence
Novel pediatric liquid	Moderate	Chemical stability and dosing accuracy
Long-acting implant or depot	Lower initially	Delivery technology and clinical development

A generic manufacturer also faces controlled-substance quotas, DEA registration, diversion controls, serialization, and supply-chain restrictions. These requirements can limit practical competition even after patent barriers fall.

Can excipients support a new dexmethylphenidate product?

Yes, but the excipient must be tied to a measurable product benefit.

Pediatric liquid opportunity

A liquid formulation could address swallowing difficulty and flexible dose titration. The principal technical risks are:

• Chemical stability in aqueous media.
• Adsorption to containers or dosing devices.
• Taste masking.
• Microbial control.
• Dose uniformity after shaking.
• Preservative compatibility.
• Container-closure performance.
• Controlled-substance dispensing controls.

Taste masking could use ion-exchange resins, polymeric coatings, sweeteners, flavors, or a suspension rather than a true solution. Each approach affects bioavailability and regulatory requirements.

Orally disintegrating tablet opportunity

An orally disintegrating tablet could improve administration for children and adults who cannot swallow tablets. Commercial value depends on:

• Rapid disintegration without friability.
• Taste masking.
• Low tablet weight.
• Uniform low-dose drug distribution.
• Packaging that limits moisture exposure.
• A bioequivalence profile acceptable for an immediate-release product.

Mannitol, crospovidone, croscarmellose sodium, and flavor systems are common platform choices, but the optimal formulation depends on compression behavior and taste performance.

Longer-duration extended-release opportunity

A once-daily formulation that extends coverage beyond the existing extended-release profile could compete on duration. Excipient platforms include:

• Water-insoluble polymer matrices.
• pH-dependent coatings.
• Osmotic systems.
• Ion-exchange resin complexes.
• Multiparticulate beads.
• Layered tablets with staged release.

The principal risk is late-day exposure. A longer duration is commercially useful only if it avoids insomnia, appetite suppression, rebound symptoms, and excessive afternoon or evening stimulant exposure.

How does dexmethylphenidate compare with methylphenidate and amphetamine products?

Dexmethylphenidate competes with racemic methylphenidate products and amphetamine-based ADHD medicines. Its excipient and formulation strategy must therefore support a distinct exposure profile.

Product category	Formulation opportunity	Competitive issue
Dexmethylphenidate IR	Low-cost tablet, ODT, liquid	High generic substitution
Dexmethylphenidate ER	Beads, matrix, osmotic delivery	Need reliable duration and PK
Racemic methylphenidate ER	Broad product variety	Larger installed prescriber base
Amphetamine ER	Capsules, tablets, liquids	Different efficacy and tolerability profile
Nonstimulant ADHD drugs	Long duration without Schedule II status	Slower onset or different efficacy

Dexmethylphenidate can be positioned around dose efficiency, tolerability, predictable onset, and administration flexibility. Excipient differentiation alone is unlikely to change prescribing behavior unless it produces a clear patient or caregiver benefit.

What licensing opportunities exist for dexmethylphenidate excipient platforms?

The most credible licensing targets are platform technologies that can be applied to multiple CNS stimulants. Potential deal structures include:

• Regional licensing of a pediatric sprinkle formulation.
• Co-development of a liquid or orally disintegrating product.
• Licensing of a multiparticulate coating process.
• Contract manufacturing for controlled-release beads.
• Acquisition of an ANDA with supply constraints.
• Use of a taste-masking platform across methylphenidate and amphetamine products.
• Development of an abuse-deterrent stimulant portfolio.

A platform is more attractive if it supports several strengths, can be manufactured at commercial scale, and has freedom-to-operate outside expired Focalin XR claims. The buyer will also assess DEA quota access, controlled-substance security, FDA inspection history, and supply of specialty coating materials.

What manufacturing and IP barriers affect commercial entry?

The principal manufacturing barriers are process control and controlled-substance compliance.

For immediate-release tablets, the critical controls are low-dose blending, segregation prevention, tablet compression, and cleaning validation. For extended-release beads, the critical controls are drug-layer uniformity, coating weight gain, polymer dispersion, spray rate, inlet temperature, and bead-size classification.

Potential IP barriers include:

• Coating architecture claims.
• Release-profile claims.
• Sprinkle-use claims.
• Manufacturing-process claims.
• Specific polymer and plasticizer combinations.
• Stability claims.
• Combination-product claims.

Freedom-to-operate analysis should cover U.S., European, Canadian, Japanese, and major emerging-market filings. Expired U.S. patents do not eliminate foreign patent risk, regulatory exclusivity, or manufacturing know-how barriers.

What is the commercial outlook for dexmethylphenidate hydrochloride?

The base generic market is competitive and price-sensitive. Growth is more likely in differentiated dosage forms than in another conventional tablet.

The most attractive opportunities are:

1. A pediatric liquid with strong taste masking and stable dosing.
2. A sprinkle-compatible extended-release capsule.
3. A lactose-free or dye-free product with reliable supply.
4. An orally disintegrating immediate-release tablet.
5. A longer-duration product with controlled late-day exposure.
6. A manufacturing platform that lowers cost for multiparticulate products.
7. A supply-secure product for shortage-prone strengths.

Revenue exposure is concentrated in branded and authorized-generic channels, while conventional generic pricing is vulnerable to supplier count and formulary substitution. A differentiated product requires evidence that the formulation improves adherence, administration, tolerability, or coverage. An excipient change without a clinically or operationally visible advantage is unlikely to support a premium.

Key Takeaways

• Dexmethylphenidate hydrochloride is a mature Schedule II ADHD stimulant with established generic competition.
• Immediate-release tablets offer low-cost entry but limited formulation differentiation.
• Extended-release multiparticulate systems provide the strongest technical and IP opportunity.
• Excipients can support commercial differentiation through release control, taste masking, sprinkle administration, capsule design, and excipient reduction.
• Focalin XR-style delivery systems face less patent-based risk than during the original branded period, but new release profiles may support follow-on protection.
• Paragraph IV risk is most relevant to newly listed formulation patents and follow-on products.
• The strongest commercial candidates are pediatric liquids, orally disintegrating tablets, sprinkle capsules, and supply-secure extended-release products.
• Patent value depends on the complete formulation and performance profile, not on use of a common excipient alone.

FAQs

Can dexmethylphenidate hydrochloride be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, selected starches, or other compatible fillers. The replacement must preserve blend uniformity, compression, disintegration, stability, and bioequivalence.

Which excipient controls the release of Focalin XR-type beads?

The release profile is primarily controlled by the polymeric coating architecture, including polymer permeability, coating thickness, pore structure, and plasticizer level. Sugar spheres and binders support bead manufacture but do not alone determine the delayed-release profile.

Is a dexmethylphenidate liquid commercially protected by existing patents?

A liquid product would require a product-specific patent and regulatory assessment. Protection could target taste masking, suspension stability, dosing accuracy, container compatibility, or a defined release and pharmacokinetic profile.

Does an excipient change require a new FDA approval?

A material excipient change in an approved generic generally requires an FDA supplement or an amended ANDA submission, depending on the change. A materially different dosage form or delivery system may require a new ANDA, 505(b)(2) application, or other regulatory pathway.

Can an extended-release dexmethylphenidate product qualify for new exclusivity?

A qualifying new formulation may obtain regulatory exclusivity if it meets statutory requirements, particularly where approval depends on essential new clinical investigations. Patent protection remains separate and requires patentable technical subject matter.

References

1. U.S. Food and Drug Administration. (2023). Focalin (dexmethylphenidate hydrochloride) tablets prescribing information.
2. U.S. Food and Drug Administration. (2023). Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules prescribing information.
3. DailyMed. (2024). Dexmethylphenidate hydrochloride tablet: labeling and inactive ingredients. National Library of Medicine.
4. DailyMed. (2024). Dexmethylphenidate hydrochloride extended-release capsule: labeling and inactive ingredients. National Library of Medicine.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
6. U.S. Food and Drug Administration. (2024). Drugs@FDA: Focalin and Focalin XR application records.
7. U.S. Patent and Trademark Office. (2024). Patent Center.
8. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
9. U.S. Code, 35 U.S.C. § 271(e)(2).